COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Gyldmark, M. [1 ]
Aultman, R. [1 ]
Siebert, U. [2 ]
Sabate, E. [3 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] UMIT Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[3] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73306-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [31] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] A randomized Phase II study of tegafur/uracil (UFT), oral Leucovorin and irinotecan, combination therapy (TEGAFIRI) plus bevacizumab versus FOLFIRI plus bevacizumab for the first-line treatment of patients with metastatic colorectal cancer
    Hasegawa, H.
    Endo, T.
    Ochiai, D.
    Uchida, H.
    Okabayashi, T.
    Imai, S.
    Ishii, Y.
    Tsuruta, M.
    Kitagawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S557
  • [33] The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
    Montero, A. J.
    Gluck, S.
    Lopes, G. D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: Safety, efficacy and genetic polymorphisms
    Bécouarn Y.
    Cany L.
    Pulido M.
    Beyssac R.
    Texereau P.
    Le Morvan V.
    Béchade D.
    Brunet R.
    Aitouferoukh S.
    Lalet C.
    Mathoulin-Pélissier S.
    Fonck M.
    Robert J.
    BMC Research Notes, 7 (1)
  • [35] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: The FIRE-3 trial (AIO KRK 0307)
    Heinemann, V
    von Weikersthal, Fischer L.
    Decker, T.
    Kiani, A.
    Verhling-Kaiser, U.
    Al Batran, S.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Stauch, M.
    Scheithauer, W.
    Hielscher, J.
    Scholz, M.
    Mueller, S.
    Schaefer, B.
    Moehler, M.
    Modest, D. P.
    Jung, A.
    Stintzing, S.
    ONKOLOGIE, 2013, 36 : 104 - 104
  • [36] A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab
    Chang, Tsung-Kun
    Yin, Tzu-Chieh
    Su, Wei-Chih
    Tsai, Hsiang-Lin
    Huang, Ching-Wen
    Chen, Yen-Cheng
    Li, Ching-Chun
    Chen, Po-Jung
    Ma, Cheng-Jen
    Chuang, Kuo-Hsiang
    Cheng, Tian-Lu
    Wang, Jaw-Yuan
    ONCOLOGY RESEARCH, 2020, 28 (7-8) : 801 - 809
  • [37] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [38] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306
    Stintzing, S.
    Neumann, J.
    Jung, A.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Modest, D. P.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
    Stintzing, S.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Giessen, C.
    Modest, D. P.
    Neumann, J.
    Jung, A.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1693 - 1699
  • [40] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
    Mitsukuni Suenaga
    Satoshi Matsusaka
    Masashi Ueno
    Noriko Yamamoto
    Eiji Shinozaki
    Nobuyuki Mizunuma
    Toshiharu Yamaguchi
    Kiyohiko Hatake
    Surgery Today, 2011, 41 : 1067 - 1074
12345